Status:
COMPLETED
Study Of SU011248 Versus Chemotherapy For Patients With Previously Treated Triple Receptor Negative Breast Cancer
Lead Sponsor:
Pfizer
Conditions:
Breast Neoplasms
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to compare progression free survival for SU011248 \[sutent (sunitinib malate)\] versus standard of care therapy in patients with previously treated, advanced, triple recep...
Eligibility Criteria
Inclusion
- Recurrent or metastatic breast cancer
- Estrogen receptor (ER), progestin receptor (PR) and HER2/neu receptor (HER2) negative status
- Prior treatment with an anthracycline and a taxane in the adjuvant or advanced disease setting
- Relapse following adjuvant chemotherapy within 6 months of last treatment and/or received one or two chemotherapy regimens for advanced disease
Exclusion
- More than two chemotherapy regimens for advanced disease
- Uncontrolled/symptomatic spread of cancer to the brain
Key Trial Info
Start Date :
January 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2011
Estimated Enrollment :
217 Patients enrolled
Trial Details
Trial ID
NCT00246571
Start Date
January 1 2006
End Date
June 1 2011
Last Update
July 12 2012
Active Locations (113)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Corona, California, United States, 92879
2
Pfizer Investigational Site
Fullerton, California, United States, 92835
3
Pfizer Investigational Site
Glendora, California, United States, 91741
4
Pfizer Investigational Site
Los Angeles, California, United States, 90095-1772